Foci Pharmaceutical(SZ:002644)2022-12-04 10:18Group 1: Company Performance and Sales - In 2017, the company achieved a sales revenue of 501 million CNY, with traditional Chinese medicine contributing 430 million CNY and herbal medicine operations over 60,000 CNY [3] - Major products with significant sales include Liuwei Dihuang Wan, Ejiao, Shenrong Guben Wan, and Xiaoyao Wan [3] - The focus for 2018 will remain on traditional Chinese medicine, with plans to enhance production and sales of classic products like Liuwei Dihuang Wan and develop exclusive products such as Ejiao and Shenrong Guben Wan [3] Group 2: Marketing and Market Expansion - The company aims to strengthen its market presence, particularly in East and South China, by optimizing product structure and increasing sales in grassroots medical units [4] - Plans include enhancing marketing team management, recruiting specialized marketing talent, and increasing advertising investment to strengthen brand image [4] Group 3: Strategic Initiatives and Collaborations - The company has been designated as one of the first research units for traditional Chinese medicine formula granules in Gansu Province and has established a strategic partnership with Tianjin Hongri Pharmaceutical [5] - The collaboration focuses on leveraging policy opportunities in traditional Chinese medicine formula granules, with plans to jointly invest in production and sales enterprises [5] Group 4: Future Plans and Reforms - Currently, there are no financing plans; however, the company intends to pursue mergers and acquisitions in the pharmaceutical sector based on its strategic development plan [5] - The company is actively seeking to promote mixed ownership reform and stock incentive plans in line with national and local government objectives for state-owned enterprise reform [6]